These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 10182565)

  • 1. Biological products regulated under Section 351 of the Public Health Service Act; implementation of biologics license; elimination of establishment license and product license; public workshop--FDA. Proposed rule; notice of workshop.
    Fed Regist; 1998 Aug; 63(154):42773-4. PubMed ID: 10182565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license; correction--FDA. Proposed rule; correction.
    Fed Regist; 1998 Sep; 63(170):46718. PubMed ID: 10182705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license--FDA. Proposed rule.
    Fed Regist; 1998 Jul; 63(147):40858-71. PubMed ID: 10181717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational new drug applications; clinical holds--FDA. Direct final rule.
    Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisions to the general safety requirements for biological products--FD. Direct final rule.
    Fed Regist; 1998 Apr; 63(75):19399-403. PubMed ID: 10178869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Guidance for industry: content and format of chemistry, manufacturing and controls information and establishment description information for a biological in vitro diagnostic product;" availability. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Mar; 64(44):11023-4. PubMed ID: 10557623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance.
    Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
    Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior notice of imported food under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Nov; 73(217):66293-410. PubMed ID: 19112701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisions to the general safety requirements for biological products; companion document to direct final rule--FDA. Proposed rule.
    Fed Regist; 1998 Apr; 63(75):19431-4. PubMed ID: 10178870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Draft guidance for industry; exports and imports under the FDA Export Reform and Enhancement Act of 1996--FDA. Notice.
    Fed Regist; 1998 Jun; 63(113):32219-34. PubMed ID: 10180275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring; extension of comment period--FDA. Proposed rule; extension of comment period.
    Fed Regist; 1998 Aug; 63(148):41219-20. PubMed ID: 10181522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA plan for statutory compliance. Notice of availability.
    Fed Regist; 1998 Nov; 63(226):65000-40. PubMed ID: 10338873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.